13F-HR filed by Patient Square Capital LP
Patient Square Capital LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-12, with 28 holding rows worth $467,131,666.
- Accession
- 0001819257-26-000002
- Filer
- CIK 1819257
- Filed
- 2026-02-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 28 entries on the cover page, a total value of $467,131,666 stated on the cover page (in dollars after the unit check, H1), rows summing to $467,131,666 with VALUE read as dollars as filed, 13F file number 028-22927. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | G76279101 | SHS | 8,166,047 | $177,203,220 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 267,000 | $46,468,680 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 298,682 | $23,592,891 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 26,000 | $21,864,700 | dollars as filed | |
| BEONE MEDICINES LTD SPONSORED ADS | 07725L102 | ADR | 69,312 | $21,057,679 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 130,000 | $17,530,500 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 542,696 | $15,059,814 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 780,000 | $14,250,600 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 320,000 | $12,928,000 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 120,000 | $11,968,800 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 317,372 | $11,273,053 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 139,000 | $10,815,590 | dollars as filed | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 227,000 | $7,829,230 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J309 | SPONSORED ADS | 359,050 | $6,882,989 | dollars as filed | |
| ALLOGENE THERAPEUTICS INC | 019770106 | COM | 4,963,756 | $6,800,346 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 150,000 | $6,181,500 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 136,500 | $6,117,930 | dollars as filed | |
| ARCUTIS BIOTHERAPEUTICS INC | 03969K108 | COM | 210,000 | $6,098,400 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 490,000 | $5,948,600 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 74,000 | $5,876,340 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 311,966 | $5,665,303 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 150,000 | $4,914,000 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 308,141 | $4,745,371 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 127,000 | $4,319,270 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 350,000 | $4,228,000 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 170,000 | $4,051,100 | dollars as filed | |
| PERSPECTIVE THERAPEUTICS INC | 46489V302 | COMMON STOCK | 1,132,815 | $3,115,241 | dollars as filed | |
| HARROW INC | 415858109 | COM | 7,031 | $344,519 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001819257-26-000002 | this filing | 2026-02-12 | acceptance time not in the bulk data set |